title: Transplantation: rituximab induction for prevention of HLA-antibody rebound.
abstract: Desensitization therapy enables HLA-incompatible transplantation. However, desensitized patients have an increased risk of antibody-mediated rejection, and the presence of donor-specific antibodies (DSAs) is associated with poor outcomes. A new study has assessed the effect of rituximab induction on DSA production in kidney transplant recipients with high immunological risk.
authors.affiliation: Department of Medicine and Department of Transplant Surgery, University of Pittsburgh Medical Center, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.
authors.forename: Puneet
authors.initials: P
authors.lastname: Sood
authors.affiliation: Department of Medicine and Department of Transplant Surgery, University of Pittsburgh Medical Center, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.
authors.forename: Sundaram
authors.initials: S
authors.lastname: Hariharan
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D016022:Case-Control Studies; D003888:Desensitization, Immunologic / Q000379:methods; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006680:HLA Antigens / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods*; D019520:Living Donors; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D000069283:Rituximab; D014181:Transplantation Immunology / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D006680:HLA Antigens; D000069283:Rituximab